Sangamo Therapeutics announced that the FDA has cleared the investigational new drug application for its ST-503 program, an investigational epigenetic regul ...
Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals third-quarter 2024 earnings conference call. (Operator Instructions) This call is being recorded on Monday, November 18, ...
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...